Actinium Pharmaceuticals has filed a patent for compositions and methods to treat cancers and proliferative disorders. The patent involves using radioconjugates targeting CD33, either alone or in combination with other cancer-associated targets, such as DR5, 5T4, HER2, HER3, and TROP2. The patent also covers antibody drug conjugates, therapeutic antibodies, chemotherapy agents, and immune checkpoint inhibitors. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Actinium Pharmaceuticals, Antibody drug conjugates(ADC) cancer therapy was a key innovation area identified from patents. Actinium Pharmaceuticals's grant share as of September 2023 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for compositions and methods for treating cancers
A recently filed patent (Publication Number: US20230302167A1) describes a method for treating various types of cancers and premalignancies in mammalian subjects, including humans. The method involves administering a radiolabeled molecule that specifically binds to CD33, a protein found on the surface of certain cells. The radiolabeled molecule can be a radiolabeled antibody, antibody fragment, antibody mimetic, peptide, ligand, or small molecule.
The patent claims specify that the radiolabeled molecule can be a radiolabeled antibody or antibody fragment, such as radiolabeled lintuzumab, radiolabeled gemtuzumab, radiolabeled vadastuximab, or any combination thereof. The radiolabel used in the molecule can be selected from a range of options, including 131I, 125I, 123I, 90Y, 177Lu, 186Re, 188Re, 89Sr, 153Sm, 32P, 225Ac, 213Bi, 213Po, 211At, 212Bi, 213Bi, 223Ra, 227Th, 149Tb, 161Tb, 47Sc, 67Cu, 134Ce, 137Cs, 212Pb, or 103Pd, or any combination thereof.
The method described in the patent can be used to treat solid tumor cancers or solid tumor premalignancies, including ovarian cancer, non-small cell lung carcinoma, head and neck squamous cell cancer, pancreatic cancer, renal cancer, breast cancer, metastatic breast cancer, tamoxifen-sensitive tamoxifen-resistant breast cancer, triple negative breast cancer, prostate cancer, castration-resistant prostate cancer (CRPC), pancreatic cancer, small cell lung carcinoma (SCLC), non-small cell lung carcinoma (NSCLC), hepatocellular carcinoma (HCC), cholangiocarcinoma, gastric cancer, colorectal cancer, esophageal cancer, or Barrett’s esophagus.
Additionally, the method can also be used to treat non-myeloid derived hematological malignancies such as lymphomas or lymphocytic leukemia, as well as haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS).
The patent also mentions the possibility of administering immune checkpoint inhibitors, such as CD47 inhibitors, PD-1 and PD-L1 inhibitors, or CTLA-4 inhibitors, in combination with the radiolabeled molecule for enhanced treatment.
Furthermore, the patent describes a method for killing myeloid-derived suppressor cells (MDSCs) in mammalian subjects with cancer or premalignancy, or those afflicted with HLH or MAS. This method involves administering a radiolabeled molecule that specifically binds to CD33 in an amount effective to kill MDSCs.
Overall, this patent presents a method for treating various types of cancers and premalignancies, as well as HLH or MAS, by administering a radiolabeled molecule that binds to CD33. The method offers potential benefits in the field of cancer treatment and may be used in combination with immune checkpoint inhibitors for improved efficacy.
To know more about GlobalData’s detailed insights on Actinium Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
